Mylan stock bounces back from early losses after CEO blames FDA for drug delays

CNBC - 9 Aug 2017 23:13

CEO Heather Bresch clarified on a call with investors that delaying Advair's launch to 2018 was due to the Food and Drug Administration reorganizing.